COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM
Michele Wilson 1
Matthew Kerrigan 2
Michael Smyth 3
Helene Chevrou-Severac 4
Annika Bergman 4
Ross Selby 5
1 RTI Health Solutions,Research Triangle Park,United States
2 PHMR Limited,London,United Kingdom
3 Takeda Development Centre Europe Ltd.,London,United Kingdom
4 Takeda Pharmaceuticals GmbH,Zurich,Switzerland
5 Takeda UK Ltd.,Bucks,United Kingdom
Conference
UEG Week 2015
Citation
United European Gastroenterology Journal; 2015: 2 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing